Present treatment options for atrial fibrillation

Postgraduate Medical Journal

Volumn 79, Issue 928, 2003, Pages 67-73

  Lairikyengbam, S K S ^a   Anderson, M H ^b   Davies, A G ^a  

^a Bronglais General Hospital   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; WARFARIN;

CARDIOVERSION; CLINICAL TRIAL; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PACING; HEART SURGERY; HUMAN; MORTALITY; REVIEW; RISK; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; ALGORITHMS; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; HUMANS; THROMBOEMBOLISM;

EID: 0037294016     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.928.67     Document Type: Review

References (55)

1. Consensus Conference on Atrial Fibrillation in Hospital and General Practice. Final consensus statement. Proc R Coll Physicians Edinb 1999;29(suppl 6):2-3.
2. Bialy D, Lehmann MH, Schumacjer DN, et al. Hospitalisation from arrhythmias in the United States: importance of atrial fibrillation (abstract). J Am Coll Cardiol 1992; 19:41 A.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
5. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Storke severily in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4.
6. Levy S, Breithardt G, Campbell RWF, et al. Working Group Report. Atrial fibrillation: current knowledge and recommendation tar management. Eur Head J 1998;19:1294-320.
7. Sopher SM, Camm AJ. Theory for atrial fibrillation: control of the ventricular response and prevention of recurrence. Coron Artery Dis 1995;6:106-14.
8. Waktare JEP, Camm AJ. How do we maintain sinus rhythm in paroxysmal atrial fibrillation. Consensus statement on atrial fibrillation in hospital and general practice. Proc R Coll Physicians Edinb 1999;29:5-12.
9. Gallagher MM, Camm AJ. Classification of atrial fibrillation. PACE 1997;20:1603-5.
10. Levy S. Classification system of atrial fibrillation. Curr Opin Cardiol 2000;15:54-7.
11. Pelosi F Jr, Morady F. Evaluation and management of atrial fibrillation. Med Clin North Am 2001;85:225-44.
12. Jais P, Haissaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997;95:572-6.
13. Daoud EG, Bogun F, Goyal R, et al. Effect of atrial fibrillation on atrial refractoriness in human. Circulation 1996;94:1600-6.
14. Ausma J, Dispersyn GD, Duimel H, et al. Change in ultrastructural calcium distribution in goat atria during atrial fibrillation. J Mol Cell Cardiol 2000;32:355-64.
15. Moe GK, Rheinboldt WC, Abildskov JA. Computer model for atrial fibrillation. Am Heart J 1964;67:200-20.
16. Reiffee JA, Camm AJ, Haffajee CI, et al. International consensus roundtable on atrial fibrillation. Cardiology Review 2000;17(suppl): 1-19.
17. Carlsson J, Neuzner J, Rosenberg YD. Therapy of atrial fibrillation: rhythm control versus rate control. PACE 2000;23:891-903.
18. Raipancholia R, Sentinella L, Lynch M. Role of conscious sedation for external cardioversion. Heart 2001;86:571-2.
19. Reisinger JJ, Gattere E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-4.
20. Capucci A, Boriani G, Botto GL, et al. Conversion of recent onset atrial fibrillation to sinus rhythm by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994;74:503-5.
21. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999;340:1849-54.
22. Anonymous. Proceeding of the American College of Chest Physicians 5th Consensus on Antithrombotic Therapy, 1998. Chest 1998;114:439S-769S.
23. Harjai KJ, Mobarek SK, Cheirif J, et al. Clinical variables affecting recovery of left atrial mechanical function after cardioversion for atrial fibrillation. J Am Coll Cardiol 1994;74:503-5.
24. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000;101:1282-7.
25. Trohman RG, Parrillo JE. Direct current cardioversion: indications, techniques and recent advances. Crit Care Med 2000;28:N170-3.
26. Taramasco V, Socas A, Ricard P, et al. Internal low-energy cardioversion: a therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion. Europace 1999;1:179-82.
27. Andrahgetti A, Scalese M. Safety and efficacy of low-energy cardioversion of 500 patients using two different techniques. Europoce 2001;3:4-9.
28. Grimm RA Transoesophageal echocardiography-guided cardiversion of atrial fibrillation. Echocardiography 2000;17:383-92.
29. Roijer A, Eskilsson J, Olsson B. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. A selection of low-risk group for immediate cardioverslon. Eur Heart J 2000;20:837-47.
30. Klein AL, Grimm RA, Murray RD, et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.
31. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation. Br Heart J 1990;63:157-61.
32. Fenelon G, Wijns W, Andries E, et al. Tachycardiomyopathy: mechanism and clinical implications. PACE 1996;19:95-106.
33. Zipes D. Specific arrhythmias: diagnosis and treatment in Braunwald's heart disease. In: Braunwald E, ed. A textbook of cardiovascular medicine. 4th Ed. Philadelphia: W B Saunders, 1992.
34. Kubec G, Malowany L. Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Can J Cardiol 1992;8:941-6.
35. Van Gelder IC, Crijns HJGM, Tieleman RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safery of oral anticoagulation. Arch Intern Med 1996;156:2585-92.
36. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-94.
37. Planning and Steering Committee of the AFFIRM Study for the NHLBI-AFFIRM Investigation. Atrial fibrillation follow-up investigation of rhythm management-design. Am J Cardiol 1997;79:1198-202.
38. Hughes S, Nainggolan L. News from the 51st Annual Scientific Session of the American College of Cardiology. Br J Cardiol 2002;9:206.
39. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of atrial fibrillation: executive summary. J Am Coll Cardiol 2001;38:1231-65.
40. Haemostasis and Thrombosis Task Force. Prepared for the British Committee for Standards in Haematology (BCSH). Guidelines on oral anticoagulation: third edition. Br J Haematol 1998;101:374-87.
41. Barwolf CG. Anticoagulation in valvular heart disease and management during non-cardiac surgery. Heart 2000;84:567-72
42. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation - analysis of pooled data from 3 randomised trials. Arch Intern Med 1997;157:1237-40.
43. Lairikyengbam SKS, Davies AG, Jones PD. Implementation of antithrombotic management in atrial fibrillation - a correspondence. Postgrad Med J 2001;77:488.
44. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-57.
45. Vardas PE. Non-pharmacological treatment of atrial fibrillation: a heretic's appraisal. PACE 2000;23:395-401.
46. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001;344:1043-51.
47. Wood MA, Kay GN, Ellenbogen KA for the APT Investigators. The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation. Europace 1999;1:22-5.
48. Andersen HR, Thensen L, Bagger J, et al. Prospective randomised trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet 1994;344:1923-8.
49. Chen SA, Hsieh MH, Tai CF, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879-86.
50. Jung J, Heisel A, Fries R, et al. Tolerability of internal low-energy shock strengths currently needed for endocardial atrial cardioversion. Am J Cardiol 1997;80:1489-90.
51. Wellen HJ, Lan CP, Luderitz B, et al. Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation 1998;98:1651-6.
52. Wijffels MCEF, Kirchhof CJHJ, Dorland RD, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instructed goats. Circulation 1995;92:1954-68.
53. Cox JL, Schuessler RB, Cain ME, et al. Surgery for atrial fibrillation. Semin Thorac Cardiovasc Surg 1989;1:67-73.
54. Cox JL, Schuessler RB, D'Agostino HJ Jr, et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991;101:569-83.
55. Cox JL, Schuessler RB, Lappas DG, et al. An 81/2-year experience with surgery for atrial fibrillation. Ann Surg 1996;224:267-75.